Dual-triggered drug-release vehicles for synergistic cancer therapy

Ting-Yu Tu; Shu-Jyuan Yang; Ming-Hsien Tsai; Chung-Hao Wang; Shin-Yu Lee; Tai-Horng Young; Ming-Jium Shieh

doi:10.1016/j.colsurfb.2018.10.043

Dual-triggered drug-release vehicles for synergistic cancer therapy

Colloids Surf B Biointerfaces. 2019 Jan 1:173:788-797. doi: 10.1016/j.colsurfb.2018.10.043. Epub 2018 Oct 19.

Authors

Ting-Yu Tu¹, Shu-Jyuan Yang², Ming-Hsien Tsai¹, Chung-Hao Wang³, Shin-Yu Lee¹, Tai-Horng Young¹, Ming-Jium Shieh⁴

Affiliations

¹ Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Section 1, Jen-Ai Road, Taipei, 100, Taiwan.
² Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Section 1, Jen-Ai Road, Taipei, 100, Taiwan; Gene'e Tech Co. Ltd. 2F., No.661, Bannan Rd., Zhonghe Dist., New Taipei City 235, Taiwan; Apius Bio Inc. 1F., No.92, Daxin St., Yonghe Dist., New Taipei City 234, Taiwan.
³ Gene'e Tech Co. Ltd. 2F., No.661, Bannan Rd., Zhonghe Dist., New Taipei City 235, Taiwan; Apius Bio Inc. 1F., No.92, Daxin St., Yonghe Dist., New Taipei City 234, Taiwan.
⁴ Institute of Biomedical Engineering, College of Medicine and College of Engineering, National Taiwan University, No. 1, Section 1, Jen-Ai Road, Taipei, 100, Taiwan; Department of Oncology, National Taiwan University Hospital, #7, Chung-Shan South Road, Taipei, 100, Taiwan; Department of Biomedical Engineering, National Taiwan University Hospital, #7, Chung-Shan South Road, Taipei, 100, Taiwan. Electronic address: soloman@ntu.edu.tw.

PMID: 30384276
DOI: 10.1016/j.colsurfb.2018.10.043

Abstract

Cancer is a complex and tenacious disease. Drug-delivery systems in combination with multimodal therapy strategies are very promising candidates for cancer theranostic applications. In this study, a new drug-delivery vehicle that combine human serum albumin (HSA)- and poly(sodium 4-styrenesulfonate) (PSS)-coated gold nanorod nanoparticles(GNR/PSS/HSA NPs) was developed for synergistic cancer therapy. Doxorubicin (DOX) was loaded onto GNR/PSS/HSA NPs, by electrostatic and hydrophobic forces, to create multimodal DOX@GNR/PSS/HSA NPs. DOX@GNR/PSS/HSA NPs were found to be highly biocompatible and stable in physiological solutions. Furthermore, GNR/PSS/HSA NPs with or without DOX were designed to exhibit strong absorbance in the near-infrared region and high photothermal conversion efficiency. Therefore, bimodal DOX release from DOX@GNR/PSS/HSA NPs could be triggered by an acidic pH and by near-infrared irradiation after NPs preferentially accumulated at tumor sites, leading to a significant chemotherapeutic effect. Moreover, DOX@GNR/PSS/HSA NPs were designed to be applied during chemo- and photo-thermal combination therapy and exhibited a synergistic anticancer effect that was superior to the effect of monotherapy, from both in vitro and in vivo results. These results suggest that DOX@GNR/PSS/HSA NPs are a strong candidate for a nanoplatform for future antitumor therapeutic strategies.

Keywords: Chemotherapy; Controlled drug release; Gold nanorod; Human serum albumin; Photothermal therapy.

MeSH terms

Animals
Antibiotics, Antineoplastic / chemistry
Antibiotics, Antineoplastic / metabolism
Antibiotics, Antineoplastic / pharmacology*
Combined Modality Therapy / methods
Delayed-Action Preparations*
Doxorubicin / chemistry
Doxorubicin / metabolism
Doxorubicin / pharmacology*
Drug Compounding / methods
Drug Liberation
Female
Gold / chemistry
HeLa Cells
Humans
Hydrogen-Ion Concentration
Infrared Rays
Injections, Subcutaneous
Low-Level Light Therapy / methods
Mice
Mice, Nude
Molecular Targeted Therapy / methods*
Nanotubes / chemistry*
Neoplasms / therapy*
Polymers / chemistry
Serum Albumin, Human / chemistry
Sulfonic Acids / chemistry
Xenograft Model Antitumor Assays

Substances

Antibiotics, Antineoplastic
Delayed-Action Preparations
Polymers
Sulfonic Acids
Gold
Doxorubicin
Serum Albumin, Human
styrenesulfonic acid polymer